233 related articles for article (PubMed ID: 29378238)
21. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
Agnihotri S; Burrell K; Buczkowicz P; Remke M; Golbourn B; Chornenkyy Y; Gajadhar A; Fernandez NA; Clarke ID; Barszczyk MS; Pajovic S; Ternamian C; Head R; Sabha N; Sobol RW; Taylor MD; Rutka JT; Jones C; Dirks PB; Zadeh G; Hawkins C
Cancer Discov; 2014 Oct; 4(10):1198-213. PubMed ID: 25100205
[TBL] [Abstract][Full Text] [Related]
22. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.
Wang Y; Yang J; Wild AT; Wu WH; Shah R; Danussi C; Riggins GJ; Kannan K; Sulman EP; Chan TA; Huse JT
Nat Commun; 2019 Feb; 10(1):943. PubMed ID: 30808951
[TBL] [Abstract][Full Text] [Related]
23. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
24. SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Sun Y; Liu X; Wu Z; Wang X; Zhang Y; Yan W; You Y
J Mol Neurosci; 2023 May; 73(4-5):259-268. PubMed ID: 37014544
[TBL] [Abstract][Full Text] [Related]
25. Silencing of ataxia-telangiectasia mutated by siRNA enhances the in vitro and in vivo radiosensitivity of glioma.
Li Y; Li L; Li B; Wu Z; Wu Y; Wang Y; Jin F; Li D; Ma H; Wang D
Oncol Rep; 2016 Jun; 35(6):3303-12. PubMed ID: 27108486
[TBL] [Abstract][Full Text] [Related]
26.
Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
[TBL] [Abstract][Full Text] [Related]
27. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
28. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
30. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
[TBL] [Abstract][Full Text] [Related]
32. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
[TBL] [Abstract][Full Text] [Related]
33. LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway.
Yang C; He L; Chen G; Ning Z; Xia Z
Hum Cell; 2019 Jan; 32(1):41-50. PubMed ID: 30426452
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Zhang P; Chen XB; Ding BQ; Liu HL; He T
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455394
[TBL] [Abstract][Full Text] [Related]
35. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.
Laverty DJ; Gupta SK; Bradshaw GA; Hunter AS; Carlson BL; Calmo NM; Chen J; Tian S; Sarkaria JN; Nagel ZD
Nat Commun; 2024 Jun; 15(1):5294. PubMed ID: 38906885
[TBL] [Abstract][Full Text] [Related]
36. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
37. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
[TBL] [Abstract][Full Text] [Related]
38. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
[TBL] [Abstract][Full Text] [Related]
39. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition.
Caporali S; Levati L; Starace G; Ragone G; Bonmassar E; Alvino E; D'Atri S
Mol Pharmacol; 2008 Jul; 74(1):173-83. PubMed ID: 18413665
[TBL] [Abstract][Full Text] [Related]
40. GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Li J; Cai J; Zhao S; Yao K; Sun Y; Li Y; Chen L; Li R; Zhai X; Zhang J; Jiang C
J Exp Clin Cancer Res; 2016 Nov; 35(1):184. PubMed ID: 27894350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
